AnHeart enters into exclusive license agreement with Nippon Kayaku to market and distribute taletrectinib in Japan

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

Patients with KRASG12C mutated-non-small cell lung cancer who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings presented during an April 30 session of the American Society of Clinical Oncology Plenary Series.

May 03, 2024

Vol.50 No.18

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Drugs & Targets

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor, or EGFR, exon 20 insertion mutations, as detected by an FDA-approved test.

March 08, 2024

Vol.50 No.10

Drugs & Targets

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

FDA granted the next-generation selective RET inhibitor EP0031/A400 Fast Track designation for the potential treatment of RET-fusion positive non-small cell lung cancer.

March 08, 2024

Vol.50 No.10

AnHeart enters into exclusive license agreement with Nippon Kayaku to market and distribute taletrectinib in Japan

YOU MAY BE INTERESTED IN

Lifileucel shrinks tumors in mNSCLC in phase II trial

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

Renew today!

Subscriber content

Login